President Trump’s FTC is taking a sledgehammer to the opaque layers of pharmacy benefit managers and middlemen who have long inflated drug prices for everyday Americans, and the ripple effects reach far beyond the medicine cabinet. By cracking down on anti-competitive practices that let a handful of gatekeepers dictate costs, the administration is proving that aggressive antitrust enforcement can deliver tangible relief to the very voters who felt forgotten by Washington’s regulatory capture. For the 2A community, this is more than a health-care story—it’s a live demonstration that the same bureaucratic machinery used to squeeze consumers on prescriptions can just as easily be turned against gun owners through backdoor rules, “ghost gun” edicts, or ATF reinterpretations that bypass Congress. When the FTC shows it can dismantle entrenched middlemen in one sector, it signals that parallel pressure on federal agencies could blunt the administrative state’s ability to erode Second Amendment rights without legislative approval. The lesson is clear: consistent, principle-driven oversight of federal power protects both pocketbooks and constitutional liberties, and the 2A community should watch these moves closely as a template for pushing back against regulatory overreach in every arena.